Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4042626 | 0.92 | CTSK (0.40) | CTSKTAS1R3TAS1R1ACESMYD3 | |
| SCHEMBL4041490 | 0.91 | CTSK (0.51) | CTSKCTSSACESMYD3PREP | |
| SCHEMBL4037649 | 0.91 | CTSK (0.51) | CTSKCTSSACESMYD3PREP | |
| SCHEMBL4040613 | 0.90 | CTSK (0.61) | CTSKCTSSACESMYD3PREP | |
| SCHEMBL4042580 | 0.89 | CTSK (0.49) | CTSKCTSS | |
| SCHEMBL3958840 | 0.89 | CTSK (0.53) | CTSKCTSSACESMYD3 | |
| SCHEMBL4037395 | 0.89 | CTSK (0.62) | CTSKCTSSACESMYD3 | |
| SCHEMBL4044081 | 0.89 | CTSK (0.51) | CTSKTAS1R3TAS1R1CTSSPREP | |
| SCHEMBL4043380 | 0.89 | CTSK (0.56) | CTSKCTSS | |
| SCHEMBL4043635 | 0.88 | CTSK (0.52) | CTSKCTSSACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-1370561-B1 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | HOFFMANN LA ROCHE (CH) | 2009-02-11 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| US-6844345-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169163-A1 | Piperazine derivatives | GPR119, SLC5A2, DPP4 | CTSK 3959/4885TAS1R3 2757/4885TAS1R1 3306/4885 |
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885TAS1R3 2219/4885TAS1R1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.